- Conditions
- Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
- Interventions
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 3,785
matching trials from the live ClinicalTrials.gov search.
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Interventions
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US)
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Chula Vista, California • Montclair, California • Sacramento, California + 9 more
- Conditions
- Critical Limb Ischemia
- Interventions
- RJX, Placebo
- Drug
- Lead sponsor
- Reven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- EGFR-Mutant Lung Cancer
- Interventions
- erlotinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- Datopotamab deruxtecan, Durvalumab, Carboplatin, AZD2936, MEDI5752, AZD7789
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 10
- States / cities
- La Jolla, California • Santa Ana, California • St Louis, Missouri + 7 more
- Conditions
- HIV Infections
- Interventions
- VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma
- Interventions
- Vaccinia virus (vvDD-CDSR)
- Biological
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Melanoma (Skin)
- Interventions
- carboplatin, paclitaxel, temozolomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Interventions
- PF-08103402, Placebo, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease
- Interventions
- Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, Cyclosporine
- Biological · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Interventions
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
- Drug · Biological
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
- Interventions
- Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Interventions
- PF-04991532, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Food Insecurity
- Interventions
- Produce prescription, Nutrition education
- Behavioral
- Lead sponsor
- Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 4
- States / cities
- Buffalo, New York
- Conditions
- Healthy Participants
- Interventions
- DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
- Drug
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Edematous Fibrosclerotic Panniculopathy, Cellulite
- Interventions
- CCH-aaes, Antifibrinolytic Agent
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- carfilzomib, belatacept, Bone marrow aspiration
- Biological · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cognitive Impairment
- Interventions
- Single Dose of VU319, Single Dose Placebo, Fed State, Fasted State, Dose Escalation of VU319, Placebo Dose Escalation
- Drug · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer
- Interventions
- VT-101
- Drug
- Lead sponsor
- Michael J. Goodheart
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Healthy
- Interventions
- PF-04634817
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Autism Spectrum Disorder
- Interventions
- Cariprazine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Orange, California • Atlanta, Georgia • Decatur, Georgia
- Conditions
- Healthy Volunteers
- Interventions
- CP-751,871, CP-751,871, moxifloxacin, saline
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
- Interventions
- Azacitidine, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- BIIB132, BIIB132-Matching Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more